Primary Immune Deficiency Treatment Consortium (PIDTC) report.
J Allergy Clin Immunol
; 133(2): 335-47, 2014 Feb.
Article
en En
| MEDLINE
| ID: mdl-24139498
Palabras clave
ADA; Adenosine deaminase; Allogeneic hematopoietic cell transplantation; CGD; CIBMTR; Center for International Blood and Marrow Transplant Research; Chronic granulomatous disease; EBMT; ESID; European Group for Blood and Marrow Transplantation; European Society for Immunodeficiencies; GT; GVHD; Gene therapy; Graft-versus-host disease; HCT; Hematopoietic cell transplantation; IEWP; Inborn Errors Working Party; MAC; MUD; Matched unrelated donor; Myeloablative conditioning; NBS; NIAID; NIH; NK; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Natural killer; Newborn screening for SCID; PID; PIDTC; Primary Immune Deficiency Treatment Consortium; Primary immunodeficiency; RIC; Reduced-intensity conditioning; SCETIDE; SCID; Severe combined immunodeficiency; Stem Cell Transplantation for Immunodeficiencies in Europe; USIDNET; United States Immunodeficiency Network; WAS; Wiskott-Aldrich syndrome; clinical trial; gene therapy; primary immunodeficiency
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Síndromes de Inmunodeficiencia
Tipo de estudio:
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
/
Newborn
Idioma:
En
Revista:
J Allergy Clin Immunol
Año:
2014
Tipo del documento:
Article